This preprint is under consideration at BMC Psychiatry. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Efficacy and safety of the adjunctive Baicalin in schizophrenia patients with negative symptoms and cognitive impairment: a randomized pilot study
Xueqin Song
The First Affiliated Hospital/Zhengzhou University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Negative symptoms and cognitive impairments are severe enough to cause predominant impairment, effective treatment is needed. We examined a new adjunctive therapy Baicalin with olanzapine in schizophrenia.
Methods Eighty-nine schizophrenia patients were treated with either olanzapine and Baicalin (Olan+Baicalin group, n=45) or olanzapine alone (Olan group, n=44) for 24 weeks. We evaluated the Positive and Negative Syndrome Scale (PANSS), cognitive function at baseline, week 12 and week 24. The treatment efficacy was investigated, with particular focus on improvements in predominant negative symptoms.
Results Our results showed significant overall reductions in including positive, negative, general psychopathology and total scores (PANSS-P, PANSS-N, PANSS-G and PANSS-T, respectively) and significantly improved cognition in Olan+Baicalin group compared with that of Olan group after 24 weeks of treatment (p’s<0.001). The observed changes in PANSS-N were independent of changes in PANSS-P and depression. After 24 weeks of treatment, significant reductions in PANSS scores and significant improvements in cognitive skills, including attention/vigilance (AV), working memory (WM), and brief visuospatial memory test (BVMT), were observed in the Olan+Baicalin group compared with the Olan group (p’s<0.05). The oxidative stress and inflammatory responses were significantly attenuated in schizophrenia patients treated with the combination of Olan+Baicalin compared with patients treated with Olan alone (p’s<0.05).
Conclusions The addition of Baicalin was effective for improving the oxidative stress, inflammation, cognition, and PANSS-N, which may provide psychiatrists with a new and safe therapeutic option for the treatment of schizophrenia.
This study is registered with Chictr.org, number ChiCTR1800016727 on 20/06/2018 (http://www.chictr.org.cn/edit.aspx?pid=27895&htm=4).
Keywords
Schizophrenia, Baicalin, Olanzapine, Cognitive function, Negative symptoms
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 21 Dec, 2020
No community comments so far
Reviewer #1 agreed
On 08 Jan, 2021
Reviewer #3 agreed
On 08 Jan, 2021
Reviewer #2 agreed
On 08 Jan, 2021
Reviewers invited
Invitations sent on 21 Dec, 2020
Editor assigned
On 21 Dec, 2020
Editor invited
On 19 Dec, 2020
Submission checks complete
On 19 Dec, 2020
First submitted
On 05 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Psychiatry
Learn more about our company.
This preprint is under consideration at BMC Psychiatry. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Efficacy and safety of the adjunctive Baicalin in schizophrenia patients with negative symptoms and cognitive impairment: a randomized pilot study
Xueqin Song
The First Affiliated Hospital/Zhengzhou University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 21 Dec, 2020
No community comments so far
Reviewer #1 agreed
On 08 Jan, 2021
Reviewer #3 agreed
On 08 Jan, 2021
Reviewer #2 agreed
On 08 Jan, 2021
Reviewers invited
Invitations sent on 21 Dec, 2020
Editor assigned
On 21 Dec, 2020
Editor invited
On 19 Dec, 2020
Submission checks complete
On 19 Dec, 2020
First submitted
On 05 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Psychiatry
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Negative symptoms and cognitive impairments are severe enough to cause predominant impairment, effective treatment is needed. We examined a new adjunctive therapy Baicalin with olanzapine in schizophrenia.
Methods Eighty-nine schizophrenia patients were treated with either olanzapine and Baicalin (Olan+Baicalin group, n=45) or olanzapine alone (Olan group, n=44) for 24 weeks. We evaluated the Positive and Negative Syndrome Scale (PANSS), cognitive function at baseline, week 12 and week 24. The treatment efficacy was investigated, with particular focus on improvements in predominant negative symptoms.
Results Our results showed significant overall reductions in including positive, negative, general psychopathology and total scores (PANSS-P, PANSS-N, PANSS-G and PANSS-T, respectively) and significantly improved cognition in Olan+Baicalin group compared with that of Olan group after 24 weeks of treatment (p’s<0.001). The observed changes in PANSS-N were independent of changes in PANSS-P and depression. After 24 weeks of treatment, significant reductions in PANSS scores and significant improvements in cognitive skills, including attention/vigilance (AV), working memory (WM), and brief visuospatial memory test (BVMT), were observed in the Olan+Baicalin group compared with the Olan group (p’s<0.05). The oxidative stress and inflammatory responses were significantly attenuated in schizophrenia patients treated with the combination of Olan+Baicalin compared with patients treated with Olan alone (p’s<0.05).
Conclusions The addition of Baicalin was effective for improving the oxidative stress, inflammation, cognition, and PANSS-N, which may provide psychiatrists with a new and safe therapeutic option for the treatment of schizophrenia.
This study is registered with Chictr.org, number ChiCTR1800016727 on 20/06/2018 (http://www.chictr.org.cn/edit.aspx?pid=27895&htm=4).
Figure 1
Figure 2
Figure 3
Figure 4